Mabwell Receives China IND Clearance for 6MW5311 Cancer Therapy
SHANGHAI, June 23, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND)...
IND clearance
Advertisement
Amphista Therapeutics Receives FDA Clearance for AMX-883 AML Trial
CAMBRIDGE, UK, June 8, 2026 Amphista Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the...
Mabwell Receives NMPA Clearance for 9MW5211 in Inflammatory Bowel Disease
SHANGHAI, China, June 5, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug...
Cellenkos Secures FDA IND Clearance for CK0802 in GVHD Trial
HOUSTON, TEXAS, May 04, 2026 Cellenkos has announced that the U.S. Food and Drug Administration (FDA) has granted Investigational...
Laguna Gains FDA IND Clearance for LGNA-100 Therapy
SAN FRANCISCO, CALIFORNIA, April 29, 2026 Laguna Biotherapeutics has announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
CanWell Pharma Secures FDA IND for CAN016 ADC Trial
WOBURN, Mass., April 1, 2026 CanWell Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
Ultragenyx Advances UX016 Into Clinical Trials for GNEM
NOVATO, Calif., March 30, 2026 Ultragenyx Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
XellSmart Secures Dual FDA, NMPA IND for MSA-P
SUZHOU, China, March 2, 2026 XellSmart Pharmaceutical Co., Ltd. announced that it has received its fourth consecutive Investigational New...
FDA Clears IND for CS2009 Trispecific Antibody Trial
SUZHOU, China, Feb. 15, 2026 — CStone Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Investigational...
FDA Clears PRD-101 Nano Cancer Drug for Phase 1
SEONGNAM, South Korea, Feb. 6, 2026 — PharmaResearch Co., Ltd. announced that the U.S. Food and Drug Administration (FDA)...
Advertisement
